COVID-19 associated mucormycosis at tertiary care hospital in South India - A retrospective study

Sahu S, Patil P, Gafurjiwala SM, Panigrahi M, Kumar Y, Nirupama AY

Pdf Page Numbers :- 154-157

Sambit Sahu^1,*, Pratik Patil¹, Seema M Gafurjiwala², Manas Panigrahi¹, Yashaswini Kumar² and Nirupama AY²

¹Krishna Institute of Medical Sciences, Minister Road, Secunderabad-500003, Telangana, India

²Indian Institute of Public Health Hyderabad, Sy. No. 384, Premavathipet Village, Rajendranagar Mandal, RR. District, Hyderabad, Telangana-500030, India

*Corresponding author: Dr. Sambit Sahu, Department of Critical and Intensive Care, Krishna Institute of Medical Sciences, Minister Road, Secunderabad-500003, Telangana, India. Email: drsambit@kimshospitals.com

Received 1 December 2022; Revised 2 March 2023; Accepted 9 March 2023; Published 17 March 2023

Citation: Sahu S, Patil P, Gafurjiwala SM, Panigrahi M, Kumar Y, Nirupama AY. COVID-19 associated mucormycosis at tertiary care hospital in South India - A retrospective study. J Med Sci Res. 2023; 11(2):154-157. DOI: http://dx.doi.org/10.17727/JMSR.2023/11-29

Copyright: © 2023 Sahu S et al. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PDF

Abstract

Background: Globally, several cases of mucormycosis have been diagnosed in patients with COVID-19, and the entity is described as COVID-19-associated mucormycosis (CAM). CAM is an emerging problem necessitating increased vigilance in COVID-19 patients, even those who have recovered. The objective was to study this cluster of cases admitted to KIMS Hospital to study the characteristics of the patients, co-morbidities, and intervention for the care.

Methods: Retrospectively reviewed EMR (Electronic Medical record) at KIMS Hospitals Secunderabad from March 2021 to October 2021. Case identification was based on the global guideline for the diagnosis and management of mucormycosis. For all cases, reverse transcription PCR (RT-PCR) result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was routinely obtained on admission, the history, the clinical presentation and course, and the radiological findings were recorded. We examined clinical features, surgical treatment approaches, medical management and type of drug used and outcomes of each case.

Results: In total 80% of case were male and all patients had an average duration of hospitalization for a week. The outcome of the Intervention at KIMS Hospital was 90.8% survival with sequelae followed by regular visit to hospital for antifungal treatment.

Conclusion: In our study we found that there was a strong association between the treatment outcome and co-morbidities (χ2 value=14.8, p-value<0.05). Improved outcome was possible because of early aggressive approach and involvement of multidisciplinary team.

Keywords: COVID-19; India; mucormycosis; CAM; severe acute respiratory syndrome coronavirus 2; SARS-CoV-2